-
UPDATE: Oppenheimer Initiates Coverage on Corcept Technologies
Friday, August 5, 2011 - 9:34am | 87Oppenheimer has initiated coverage on Corcept Therapeutics (NASDAQ: CORT), and has also published a report on the event. In the report, Oppenheimer wrote, "We are initiating coverage of Corcept Therapeutics with an Outperform rating. Our positive outlook and valuation of the stock is based on the...
-
DB Changes PT And EPS Estimates Of Valeant
Friday, August 5, 2011 - 9:07am | 42According to DB, Valeant Pharmaceuticals (NYSE: VRX), PT and EPS estimates have changed. DB reported a decrease in the PT from $64.00 to $57.00 and a change in EPS estimates from $2.78 to $2.84. Valeant closed yesterday at $40.85.
-
Oppenheimer Initiates Corcept Therapeutics At Outperform, $8 PT
Friday, August 5, 2011 - 8:37am | 24Oppenheimer has initiated coverage on Corcept Therapeutics (NASDAQ: CORT) with an Outperform rating and $8 price target.
-
Alexza Announces Resubmission of AZ-004 NDA
Friday, August 5, 2011 - 8:32am | 72Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has resubmitted its AZ-004 New Drug Application to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Lette received in October 2010. The Company believes this is a Class 2 resubmission with a six-month...
-
Deutsche Bank Lowers PT on Valeant Pharmaceuticals To $57
Friday, August 5, 2011 - 7:46am | 27Deutsche Bank has lowered the price target on Valeant Pharmaceuticals (NYSE: VRX) from $64 to $57 and maintains its Buy rating.
-
UPDATE: Piper Jaffray Lowering Price Target On Valeant Pharmaceuticals
Friday, August 5, 2011 - 7:36am | 181Piper Jaffray is out with a research report on Valeant Pharmaceuticals (NYSE: VRX) and is lowering its price target to $51 from $65, but is keeping its Overweight rating on shares. In a note to clients, Piper Jaffray writes, "Yesterday, Valeant reported cash EPS of $0.66 (not including a gain of...
-
VIVUS Announces Study Showing Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
Friday, August 5, 2011 - 7:33am | 161VIVUS, Inc. (NASDAQ: VVUS) today announced that additional data from the phase 3 QNEXA studies will be presented today during the American Association of Diabetes Educators meeting in Las Vegas, NV. Ronette L. Kolotkin, PhD, a clinical psychologist from Obesity and Quality of Life Consulting,...
-
Piper Jaffray Lowers PT On Valeant Pharmaceuticals To $51
Friday, August 5, 2011 - 6:38am | 27Piper Jaffray has lowered the price target on Valeant Pharmaceuticals (NYSE: VRX) from $65 to $51 and maintains its Overweight rating.
-
Ex-MLB Player Doug DeCinces Charged with Insider Trading by SEC -CNN Money
Thursday, August 4, 2011 - 4:27pm | 76The SEC today charged former pro baseball player Doug DeCinces with insider trading, alleging that he and three associates pocketed more than $1.7 million from buying shares in a company that was about to announce an acquisition by Abbott Laboratories (NYSE: ABT). Each of the four have since...
-
McNicoll, Lewis & Vlak Lowers SuperGen PT, Maintains Buy
Thursday, August 4, 2011 - 4:02pm | 105McNicoll, Lewis & Vlak lowered its SuperGen (NASDAQ: SUPG) price target from $8 to $6.50 and maintained its SuperGen Buy rating in a research report published today. In the report, McNicoll, Lewis & Vlak states, "We expect significant changes in SuperGen's pipeline following a portfolio...
-
Options Brief: Mylan
Thursday, August 4, 2011 - 2:00pm | 73Shares of Mylan (NYSE: MYL) are lower on the session by 3.48%, trading at $19.70. Overall put volume is now running at 4.81x the daily average, with 95% of all puts traded being purchases on the offer. 10,057 contracts have traded on the session so far. Mylan Inc. and its subsidiaries is a...
-
Options Brief: Auxilium Pharmaceuticals
Thursday, August 4, 2011 - 10:08am | 96Shares of Auxilium Pharmaceuticals (NASDAQ: AUXL) are lower on the session by 6.05%, trading at $15.05. Overall call volume is now running at 15.32x the daily average, with 3% of all calls traded being purchases on the offer. 2,650 contracts have traded on the session so far. Auxilium...
-
Amarin Announces Phase 3 ANCHOR and MARINE Trial Data to be Presented in November at the American Heart Association's Scientific Sessions
Thursday, August 4, 2011 - 8:20am | 111Amarin Corporation plc (Nasdaq: AMRN) today announced that data from each of its two pivotal Phase 3 studies, the ANCHOR trial and the MARINE trial, will be presented at the American Heart Association's Scientific Sessions 2011 in Orlando, Fla. The presentation of the ANCHOR trial results will be...
-
Jefferies Rating and PT Updates 8/4
Thursday, August 4, 2011 - 8:12am | 1311Jefferies made a number of rating and price target changes in a research report published today. AstraZeneca PLC (NYSE: AZN) had its rating upgraded from Underperform to Hold. On Wednesday, AZN lost 0.34% of its value to finish the day at $47. Its shares continued to slide in today's pre-market...
-
Piper Jaffray Downgrades Allergan To Neutral
Thursday, August 4, 2011 - 8:04am | 106According to Piper Jaffray, Allergan (NYSE: AGN) reported 2Q11 EPS of $0.96, beating the Street estimate of $0.95, driven by continued strength for Botox, the eye care business and facial aesthetics. Piper Jaffray said that though management has positioned the company for sustained annual double-...